All In Biotech

Free tool

FAERS Monitor: Iressa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206995 or its brand name (Iressa, Gefitinib). Reports on generic versions are filed under their own applications.

Reports

8,993

Serious

8,525

95% of reports

Hospitalization

2,580

Death reported

1,955

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • malignant neoplasm progression1,824
  • drug resistance1,253
  • diarrhoea907
  • death758
  • rash643
  • disease progression462
  • interstitial lung disease420
  • nausea380
  • metastases to central nervous system377
  • dyspnoea332
  • vomiting326
  • drug ineffective299
  • pneumonia271
  • pyrexia270
  • acquired gene mutation259

Reports by year received

View as table
YearReports
2004801
2005515
20061,182
2007235
2008214
2009194
2010240
2011333
201287
201337
201448
2015239
2016503
2017557
2018614
2019990
2020713
2021430
2022278
2023283
2024249
2025181
202670

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,166 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acquired gene mutationSignal259576.1503.7118,872
drug resistanceSignal1,253119.9113.7140,573
metastases to central nervous systemSignal37770.463.724,983
malignant neoplasm progressionSignal1,82442.440.772,721
interstitial lung diseaseSignal42020.518.67,703
disease progressionSignal4629.28.43,358
rashSignal6433.53.21,140
diarrhoeaSignal9073.33.11,487
deathSignal7582.11.9429
pneumonia2712.01.7128
pyrexia2701.81.6102
vomiting3261.61.579
dyspnoea3321.41.234
nausea3801.11.05
drug ineffective2990.50.5132

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.